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Silencing Nﬁx rescues muscular dystrophy by
delaying muscle regeneration
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Muscular dystrophies are severe disorders due to mutations in structural genes, and are
characterized by skeletal muscle wasting, compromised patient mobility, and respiratory
functions. Although previous works suggested enhancing regeneration and muscle mass as
therapeutic strategies, these led to no long-term beneﬁts in humans. Mice lacking the
transcription factor Nﬁx have delayed regeneration and a shift toward an oxidative ﬁber type.
Here, we show that ablating or silencing the transcription factor Nﬁx ameliorates pathology in
several forms of muscular dystrophy. Silencing Nﬁx in postnatal dystrophic mice, when the
ﬁrst signs of the disease already occurred, rescues the pathology and, conversely, Nﬁx
overexpression in dystrophic muscles increases regeneration and markedly exacerbates the
pathology. We therefore offer a proof of principle for a novel therapeutic approach for
muscular dystrophies based on delaying muscle regeneration.
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Muscular dystrophies (MDs) are inherited skeletal muscledisorders characterized by progressive muscle damageand weakness of variable distribution and severity,
leading to wheelchair dependency and, in the most severe cases,
to patient’s death1, 2. MDs are due to mutations in genes encoding
for proteins of the structural dystrophin-glycoprotein complex,
which induce sarcolemmal instability and muscle necrosis. The
most common form is Duchenne muscular dystrophy (DMD), an
X-linked autosomal recessive disorder due to mutations in the
dystrophin gene, which encodes a protein anchoring the sarco-
lemmal membrane to the cytoskeleton, thus protecting the ﬁbers
from contraction-induced damage3. Another form is limb girdle
muscular dystrophy 2D, an autosomal recessive disorder caused
by mutations in the α-sarcoglycan gene4 and part of a group of
MDs, with a prevalence ranging from 1 in 14,500 to 1 in
123,0005, 6.
Unfortunately, there is no effective therapy, and corticosteroids
represent the most widely used treatment to counteract chronic
inﬂammation7. Although many attempts have been done to
design cell and gene therapies, these approaches are limited by
technical issues, related to difﬁculties in ﬁnding the appropriate
cell type or vector, and are therefore still far to be curative8, 9. A
shared knowledge in the ﬁeld is that to be really successful, any
therapeutic approach has to rely on good muscle quality, there-
fore restricting the number of patients eligible for clinical trials. In
fact, there is no available approach able to rescue muscle damage
when the muscle tissue has been completely lost and substituted
by ﬁbrotic deposits, thus restricting the cohort of patients eligible
for clinical trials to the youngest and less compromised indivi-
duals. Therefore, many groups proposed drugs and genetic con-
structs to counteract skeletal muscle degeneration by promoting
regeneration by endogenous satellite cells10, 11. Nevertheless, none
of these strategies demonstrated to be efﬁcacious when translated
to humans12, and there is still the need for alternative approaches
and new targets to be identiﬁed. MDs are indeed characterized by
continuous cycles of degeneration and regeneration, as a con-
sequence of the attempt to repair damage by satellite stem cells
that unfortunately, sharing the same mutation of the myoﬁbers,
are not able to successfully repair damage, leading to the loss of
muscle tissue and establishment of ﬁbrosis. Interestingly, it has
been shown that slow-twitch, oxidative ﬁbers are more protected
from damage-induced oxidative stress and degeneration13–16. In
light of our recent observation that mice lacking Nﬁx are
characterized by a delayed regeneration after injury and a switch
toward a slow-twitch phenotype17, 18, we hypothesized that
targeting Nﬁx in a dystrophic context may exert a protective
effect.
Nﬁx is part of a family of four closely related transcription
factors (Nﬁa, b, c, and x) with a role in activating/repressing
transcription of genes expressed in various organs19–25. We
previously demonstrated that Nﬁx is responsible for the tran-
scriptional switch from embryonic to fetal myogenesis, a crucial
checkpoint during muscle development. In particular, fetuses
lacking Nﬁx are characterized by a slow-twitch musculature,
typical of the embryonic period, while embryos overexpressing
Nﬁx switch to a more mature fetal-like phenotype17. In addition,
we recently observed that, postnatally, Nﬁx is crucial for the
maintenance of the correct timing of skeletal muscle regeneration
upon injury18.
Here, we show that silencing Nﬁx in both α-sarcoglycan (Sgca
null)- and dystrophin (mdx)-deﬁcient dystrophic mice strikingly
protects from the degenerative process by promoting a more
oxidative musculature and by slowing down muscle regeneration,
in contrast to previous attempts that aimed to promote regen-
eration. These data are supportive of a new role for Nﬁx in the
progression of MD and suggest Nﬁx as a novel target to treat this
severe disease. More in general, we provide proof of principle for
an innovative therapeutic approach based on the idea that
slowing down the degeneration–regeneration cycles, instead of
increasing regeneration, delays the progression of the pathology.
Results
Absence of Nﬁx improves dystrophic signs of Sgca null mice.
To verify whether the muscle phenotype observed in the Nﬁx null
mouse17, 18 would be beneﬁcial in a dystrophic context, we
generated dystrophic mice lacking Nﬁx. The Sgca null mouse
model26 was chosen for our analysis because of its very severe
phenotype, resembling the human pathology. Muscle histology
was analyzed at different weeks of age, to monitor the progression
of the disease. At 3 weeks, the ﬁrst signs of aberrant muscle
structure were already present in Sgca null mice (Fig. 1a), char-
acterized by few regenerative ﬁbers (Supplementary Fig. 1A) and
presence of inﬂammatory inﬁltrates, necrotic areas, and varying
ﬁber calibre. On the contrary, Sgca null:Nﬁx null mice were
characterized by a compact structure with less interstitial space
between myoﬁbers and absence of large degenerative areas. At
5 weeks, Sgca null mice showed increased central nucleation
(Fig. 1b and Supplementary Fig. 1B), a typical sign of ongoing
regeneration, and presence of degenerated and inﬂammatory
areas. This was particularly evident in the diaphragm, one of the
most affected muscles in the pathology27, 28. At the same age, Sgca
null:Nﬁx null skeletal muscles still appeared less damaged, with
reduced central nucleation and few inﬂammatory areas (Fig. 1b
and Supplementary Fig. 1B). At 8 weeks, inﬂammation, degen-
eration, and central nucleation were predominant in Sgca null
mice, while still evidently reduced in Sgca null:Nﬁx null mice
(Fig. 2a and Supplementary Fig. 1C). At 12 weeks, endomysial
ﬁbrosis was diffuse in Sgca null mice, together with a marked ﬁber
atrophy and further exacerbation of all the other histological signs
(Fig. 2b). As observed in the previous time points, even at
12 weeks, muscle morphology was improved in the absence of
Nﬁx (Fig. 2b and Supplementary Fig. 1D). The improvement of
the histopathological signs of the disease as percentage of cen-
trally nucleated ﬁbers has been quantiﬁed at 3, 5, 8, and 12 weeks,
revealing a statistically signiﬁcant amelioration in the Sgca null:
Nﬁx null mice with respect to control Sgca null mice, thus con-
ﬁrming our hypothesis that the delayed regenerative phenotype of
Nﬁx null mice18 is beneﬁcial in a dystrophic context and is one of
the mechanisms of the observed muscular improvement (Sup-
plementary Fig. 1A–D). Moreover, as shown in Supplementary
Fig. 1E, F, at 8 weeks, the cross-sectional area (CSA) of the
myoﬁbers, which has a non-homogeneous distribution in Sgca
null mice, is completely rescued in dystrophic mice lacking Nﬁx,
which appear similar to wild type (WT). Notably, the analysis of
other limb muscles at 8 weeks clearly conﬁrmed that the striking
histological amelioration of Sgca null:Nﬁx null mice is a common
feature for all muscles (Supplementary Fig. 2A, B). Most impor-
tantly, this morphological improvement persisted over time in the
Sgca null:Nﬁx null mice, at least up to 6 months, when in Sgca
null animals, particularly in the diaphragm, muscle necrosis is
massive, and fat and ﬁbrotic tissue replaced, almost completely,
the damaged musculature (Fig. 2c).
Overall, this analysis showed that absence of Nﬁx in Sgca null
mice leads to a striking morphological improvement that persists
over time up to at least 6 months.
Sgca null:Nﬁx null mice show morpho-functional rescue. To
further conﬁrm and quantify the histological amelioration
observed in Sgca null:Nﬁx null mice, we measured other impor-
tant hallmarks characterizing dystrophic muscles at 8 weeks.
Precisely, in order to evaluate sarcolemmal integrity, we
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systemically injected Evan’s blue dye in Sgca null and Sgca null:
Nﬁx null mice. As shown in Fig. 3a–c, we observed a statistically
signiﬁcant decrease in the percentage of Evan’s blue dye (EBD)
positive ﬁbers in Sgca null:Nﬁx null mice if compared to dys-
trophic Sgca null mice, reﬂecting a higher sarcolemmal integrity
in mice lacking Nﬁx. Moreover, collagen I deposit areas were
quantiﬁed by immunoﬂuorescence, demonstrating a signiﬁcant
reduction in Sgca null:Nﬁx null mice (Fig. 3d and Supplementary
Fig. 2C). These histological ameliorations were also accompanied
by a reduction of the inﬂammatory parameters, which were
measured through an ELISA assay to detect MIP-2 concentration
in muscle (Fig. 3e). In addition, we performed immuno-
ﬂuorescence analysis for F4/80 (a macrophage marker) and
quantiﬁed the number of F4/80+ macrophages per muscle area.
As shown in Fig. 3f, the number of macrophages is reduced in
double-mutant Sgca null:Nﬁx null mice, with respect to Sgca null
mice. Notably, this difference is statistically signiﬁcant starting
from week 8, when macrophage inﬁltration begins to be massive
in Sgca null mice.
Most importantly, as a consequence of this morphological
amelioration, we observed the rescue of the functional ability of
double-mutant mice, measuring muscle performance with a
treadmill test. Graphs in Fig. 4a, b and Supplementary Movie 1
evidence that dystrophic mice lacking Nﬁx are characterized by a
better performance, almost comparable to the one of WT mice.
Interestingly, the best muscle performance was observed in Nﬁx
null animals, which run with a higher resistance to fatigue even
with respect to WT mice.
Delayed regeneration and oxidative musculature improve
MDs. The results showed so far clearly demonstrate that the
amelioration of the dystrophic phenotype observed in absence of
Nﬁx is, in part, due to a delay in muscle regeneration. We have
already demonstrated that lack of Nﬁx leads to a delay of muscle
regeneration upon acute cardiotoxin (CTX) injury18. We further
investigated this concept in dystrophic Sgca null:Nﬁx null mice by
looking at developmental MyHC expression relative to central
nucleation at different time points, in both Sgca null and Sgca
null: Nﬁx null mice. As shown in the graph in Fig. 4c, we con-
ﬁrmed that regeneration is delayed in Sgca null:Nﬁx null mice,
whose muscles start to massively regenerate later with respect to
control Sgca null mice (see difference between time point 3 and
5 weeks). This analysis, together with the quantiﬁcation of the
centrally nucleated ﬁbers (Supplementary Fig. 1A–D) and the
measurement of the myoﬁber CSA (Supplementary Fig. 1E, F),
provide direct evidence that Sgca null:Nﬁx null mice have a
delayed regeneration with respect to Sgca null mice.
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Fig. 1 Lack of Nﬁx improves signs of muscular dystrophy. a Hematoxylin and eosin (H&E) and Milligan’s trichrome staining of tibialis anterior (left) and
diaphragm (right) muscles at 3 weeks of age; N= 12 Sgca null and 6 Sgca null:Nﬁx null mice. Scale bar 100 μm. b Hematoxylin and eosin (H&E) and
Milligan’s trichrome staining of tibialis anterior (left) and diaphragm (right) muscles at 5 weeks of age; N= 5 Sgca null and 5 Sgca null:Nﬁx null mice. Scale
bar 100 μm. See also Supplementary Fig. 1 for the analysis of central nucleation in tibialis anterior and diaphragm muscles at 3 and 5 weeks
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Fig. 2 Muscular dystrophy amelioration in absence of Nﬁx persists up to 6 months. a Hematoxylin and eosin (H&E) and Milligan’s trichrome staining of
tibialis anterior (left) and diaphragm (right) muscles at 8 weeks of age; N= 23 Sgca null and 12 Sgca null:Nﬁx null mice. Scale bar 100 μm. b Hematoxylin
and eosin (H&E) and Milligan’s trichrome staining of tibialis anterior (left) and diaphragm (right) muscles at 12 weeks of age; N= 6 Sgca null and 4 Sgca
null:Nﬁx null mice. Scale bar 100 μm. c Hematoxylin and eosin (H&E) and Milligan’s trichrome staining of tibialis anterior (left) and diaphragm (right)
muscles at 6 months of age; N= 4 Sgca null and 4 Sgca null:Nﬁx null mice. Scale bar 100 μm. See also Supplementary Fig. 1 for the analysis of central
nucleation in tibialis anterior and diaphragm muscles at 8 and 12 weeks and for the analysis of CSA at 8 weeks, Supplementary Fig. 2 for full muscle
reconstructions, collagen I quantiﬁcation, histology of gastrocnemius, quadriceps, soleus, and EDL muscles, and PCR analysis of oxidative ﬁber genes at
8 weeks, and Supplementary Fig. 3 for the analysis of utrophin and myostatin levels at 8 weeks
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To verify whether the improvements observed in dystrophic
mice lacking Nﬁx could be also attributed to a more oxidative
phenotype, we performed a succinate dehydrogenase (SDH)
staining, which highlights in blue the presence of oxidative ﬁbers.
Strikingly, dystrophic Sgca null mice lacking Nﬁx displayed a
more oxidative phenotype at 3 weeks (Fig. 4d), consistent with
the higher resistance to fatigue observed by treadmill test (Fig. 4a,
b, Supplementary Movie 1). Additionally, we performed a real-
time PCR analysis of typical markers of the oxidative phenotype
(SDHA, SDHB, and Cox5)29–31 in different muscles at 3 weeks.
As shown in the graphs in Supplementary Fig. 2D–F, all markers
were signiﬁcantly upregulated in Sgca null:Nﬁx null mice, in both
slow-twitch and fast-twitch muscles, thus further demonstrating a
general switch toward an oxidative metabolism in the Sgca null:
Nﬁx null mice, regardless the muscle ﬁber type.
A previous work showed that switch toward slow-twitch ﬁbers
upon modulation of Ca2+/calmodulin signaling leads to utrophin
upregulation in mdx mice, thus ameliorating the phenotype32.
We therefore looked at utrophin expression in single- and
double-dystrophic mice, without observing signiﬁcant differences
(Supplementary Fig. 3A). These data exclude utrophin upregula-
tion as a possible mechanism.
In line with this, previous literature claimed that myostatin
blockade exerts positive effects on the dystrophic
phenotype10, 33, 34 and, interestingly, we recently reported that
during acute injury Nﬁx is able to modulate myostatin expression
during satellite cell differentiation18. We therefore veriﬁed
myostatin expression in Sgca null:Nﬁx null mice. As shown in
Supplementary Fig. 3B, C, both myostatin messenger RNA
expression (Supplementary Fig. 3C) and serum levels
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Fig. 3 Pathological parameters are rescued in dystrophic mice lacking Nﬁx. a Percentage of EBD positive myoﬁbers in tibialis anterior muscles at 8 weeks;
N= 19 Sgca null and 9 Sgca null:Nﬁx null mice; mean± SD; t test, *P< 0.05. b Percentage of EBD positive myoﬁbers in diaphragms at 8 weeks; N= 19 Sgca
null and 11 Sgca null:Nﬁx null mice; mean± SD; t test, *P< 0.05. c Immunoﬂuorescence for laminin (green) and EBD (red) on diaphragms at 8 weeks.
Hoechst (blue) stains nuclei. Scale bar 50 μm. d Immunoﬂuorescence showing collagen I (green) deposits in tibialis anterior sections. Scale bar 100 μm. e
MIP2 ELISA assay on gastrocnemius muscles at 8 weeks; N= 18 Sgca null and 7 Sgca null:Nﬁx null mice; mean± SD; t test, *P< 0.05. f Quantiﬁcation of the
immunoﬂuorescence staining for F4/80, marker of macrophages (MPs), on tibialis anterior muscle sections at different time points. N= 5 Sgca null and 5
Sgca null:Nﬁx null at 3 weeks, N= 3 Sgca null and 3 Sgca null:Nﬁx null at 5 weeks, N= 8 Sgca null and 8 Sgca null:Nﬁx null at 8 weeks, and N= 12 Sgca null
and 7 Sgca null:Nﬁx null at 12 weeks. Mean± SEM; t test, *P< 0.05, ***P< 0.001
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(Supplementary Fig. 3B) were similar in all mice analyzed. This
result is in keeping with our previous observation that Nﬁx is able
to modulate myostatin expression speciﬁcally during the
regeneration phase18. This implies that the improvement
observed in Sgca null:Nﬁx null mice is not mediated by a
downregulation of myostatin.
Overexpression of Nﬁx exacerbates the dystrophic disease.
Based on the positive results that we obtained targeting Nﬁx in
dystrophic mice, we decided to further investigate the link
between Nﬁx expression and the progression of the pathology.
We therefore generated a dystrophic mouse model overexpressing
Nﬁx downstream a skeletal muscle promoter, taking advantage of
Tg:Mlc1f-Nﬁx2 mice17. Histological analysis of Sgca null:Mlc1f-
Nﬁx2 mice revealed a markedly worsened phenotype with respect
to Sgca null mice, both at 5 (Fig. 5a) and 8 weeks (Fig. 5b). This
was evident in terms of presence of necrotic, ﬁbrotic, and
inﬂammatory areas (Fig. 5a, b), and was accompanied by an
increase of central nucleation (Fig. 5c) and a less homogeneous
distribution of myoﬁber CSAs, with the co-presence in the same
muscles of small and hypertrophic ﬁbers (Fig. 5d and Supple-
mentary Fig. 4D). Interestingly, while observing muscle histology
of Sgca null:Mlc1f-Nﬁx2 mice, we encountered a strong pheno-
typic variability, with impressive exacerbation of the phenotype in
some cases, and only a milder exacerbated phenotype in others.
We reasoned that this could be explained by the transgenic
construct used to generate Tg:Mlc1f-Nﬁx2 mice. In fact, in these
mice, overexpression of Nﬁx is guided by a BAC (bacterial arti-
ﬁcial chromosome), which carries the Mlc1f-Nﬁx2 transgene17.
Since transgene expression in this case may depend on both BAC
copy number and transgene expression efﬁciency, we decided to
classify Nﬁx overexpressing mice based on their level of transgene
overexpression. We evaluated Nﬁx expression in skeletal muscles
of Sgca null and Sgca null:Mlc1f-Nﬁx2 mice, and classiﬁed each
mice in one of three subclasses, based on Nﬁx overexpression
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Fig. 4 Sgca null:Nﬁx null mice show improved functionality, an oxidative phenotype, and delayed regeneration. a, b Treadmill test on WT, Sgca null, Sgca
null:Nﬁx null, and Nﬁx null mice. a represents the performance proﬁle over time, while b shows the totality of the measurements; N= 6 measurements per
7 WT, 4 Sgca null, 3 Sgca null:Nﬁx null, and 4 Nﬁx null mice. Mean± SD; one-way ANOVA with Bonferroni post-test, ***P< 0.001. ns, non signiﬁcant. See
also Supplementary Movie 1 for an example of a typical run. c Percentage of developmental myosin heavy chain positive ﬁbers out of the centrally
nucleated ﬁbers at different time points. N= 8 Sgca null and 8 Sgca null:Nﬁx null mice at 3 weeks, N= 11 Sgca null and 11 Sgca null:Nﬁx null mice at 5 weeks,
N= 11 Sgca null and 11 Sgca null:Nﬁx null mice at 8 weeks, and N= 10 Sgca null and 10 Sgca null:Nﬁx null mice at 12 weeks; mean± SEM; t test, *P< 0.05,
*P< 0.001. d Entire tibialis anterior muscle section reconstructions and higher magniﬁcations showing SDH staining at 3 weeks of age; N= 13 Sgca null and
6 Sgca null:Nﬁx null mice. Scale bar 100 μm
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01098-y
6 NATURE COMMUNICATIONS | 8:  1055 |DOI: 10.1038/s41467-017-01098-y |www.nature.com/naturecommunications
with respect to Sgca null mice, whose expression was considered
as 1. As shown in Supplementary Fig. 4A, B, a high variability was
observed among Sgca null:Mlc1f-Nﬁx2mice, in terms of transgene
expression. In some mice, Nﬁx expression was only slightly
increased with respect to Sgca null mice (class 1–4), while others
had an intermediate (class 4–10) or very high expression of the
transgene (>10-fold expression with respect to Sgca null mice).
Interestingly, mice with a very high overexpression of Nﬁx
(belonging to the >10 class) showed a more marked exacerbation
of the phenotype, which we quantiﬁed in terms of central
nucleation (Supplementary Fig. 4C). In fact, mice belonging to
the >10 class were characterized by a higher central nucleation
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Fig. 5 Nﬁx overexpression in skeletal muscle exacerbates the dystrophic phenotype. a Hematoxylin and eosin (H&E) and Milligan’s trichrome staining of
tibialis anterior (left) and diaphragm (right) muscles at 5 weeks of age; N= 4 Sgca null and 9 Sgca null:Mlc1f-Nﬁx2 mice. Scale bar 100 μm. b Hematoxylin
and eosin (H&E) and Milligan’s trichrome staining of tibialis anterior (left) and diaphragm (right) muscles at 8 weeks of age; N= 6 Sgca null and 30 Sgca
null:Mlc1f-Nﬁx2 mice. Scale bar 100 μm. c Percentage of centrally nucleated myoﬁbers in tibialis anterior muscles at 8 weeks of age; N= 11 Sgca null and 18
Sgca null:Mlc1f-Nﬁx2 mice. Mean± SD; t test, ***P< 0.001. d Myoﬁber cross-sectional area distribution at 8 weeks of age; N= 186 ﬁbers for WT, 908 for
Sgca null, and 1026 for Sgca null:Mlc1f-Nﬁx2 mice. Mean±whiskers from min to max; one-way ANOVA with Bonferroni post-test, ***P< 0.001. See also
Supplementary Fig. 4 for PCR and WB analysis of Nﬁx expression in Sgca null:Mlc1f-Nﬁx2 mice, as well as for central nucleation and CSA measurements
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with respect not only to Sgca null mice, but also with respect to
Sgca null:Mlc1f-Nﬁx2 mice belonging to class 1–4. Histological
stainings shown in Fig. 5 refer to the highest class of Nﬁx
expression, chosen as the most representative.
Lack of Nﬁx also protects the mdx dystrophic muscles. In light
of the striking amelioration that we observed in Sgca null mice,
we veriﬁed whether our approach could be applied to other MDs.
To this aim, we deleted Nﬁx in mdx mice, the mouse model for
DMD, the most common form of muscular dystrophy in
humans35.
As shown in Fig. 6a, mdx:Nﬁx null mice showed a milder
phenotype compared to mdx controls. The improvement was
evident in terms of muscle structure and presence of necrotic,
ﬁbrotic, and inﬂammatory areas, in both tibialis anterior and
diaphragm muscles (Fig. 6a). To understand whether the
phenotypic amelioration was mediated by a delayed regeneration,
similarly to what observed for Sgca null:Nﬁx null mice, we
measured central nucleation in tibialis anterior and diaphragm
muscles of mdx and mdx:Nﬁx null mice. As expected, we
observed a signiﬁcant decrease in the percentage of centrally
nucleated ﬁbers in mdx:Nﬁx null mice, compared to mdx
(Fig. 6b).
Overall, the data shown demonstrate that lack ofNﬁx leads to a
rescue of the histopathological signs of the dystrophic disease,
with reduced central nucleation and a better muscle histology,
regardless of the genetic defect.
Silencing Nﬁx in adult Sgca null mice rescues MD signs. The
results shown so far have clearly demonstrated that genetic
ablation of Nﬁx in dystrophic animals causes a signiﬁcant
improvementof the disease, thus protecting from muscle degen-
eration. In light of a future translational approach, we wondered
whether absence of Nﬁx might lead to the same effects observed
even when the dystrophic disease already occurred, which
represents what would normally be feasible in patients.
To this aim, we electroporated the tibialis anterior of 5-week-
old Sgca null mice with control (scramble) or shNﬁx
plasmids17, 18. Muscles were analyzed 1 and 2 days after
electroporation to verify Nﬁx silencing (Fig. 7a), and 2 weeks
later to verify its effect on muscle (Fig.7b, c). We observed a
striking rescue of the dystrophic muscle morphology in terms of
reduced inﬁltrates, centrally nucleated myoﬁbers, and CSA
distribution in Sgca null muscles silenced for Nﬁx if compared
with the contralateral muscles where the main hallmarks of
muscular dystrophy already appeared (Fig. 7b–f). Consistently,
this phenotypical rescue is also due to a more oxidative
musculature, as observed by the SDH staining (Fig. 7g). More-
over, this result is accompanied by a robust reduction of the
collagen I deposits (Fig. 7h).
Discussion
MDs are severe inherited muscle disorders that still lack an
effective therapy. The typical feature of the pathology is the
succession of cycles of degenerations followed by attempts to
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Fig. 6 Targeting Nﬁx ameliorates muscular dystrophy also in mdx mice. a Hematoxylin and eosin (H&E) and Milligan’s trichrome staining of tibialis
anterior (left) and diaphragm (right) muscles at 10 weeks of age; N= 5 mdx and 4 mdx:Nﬁx null mice. Scale bar 100 μm. b Percentage of centrally
nucleated myoﬁbers in tibialis anterior (TA) and diaphragm muscles at 10 weeks of age; N= 5 mdx and 4 mdx:Nﬁx null mice for TA. N= 8 mdx and 5 mdx:
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regenerate the damage, which not only fail to successfully repair
the muscle, but also foster the degenerative process.
Here, we show that targeting the transcription factor Nﬁx in
dystrophic mice induces a protective effect from the progression
of the pathology with striking improvements of both morpholo-
gical and functional muscle properties. This is achieved through a
mechanism acting at different levels: Nﬁx is able not only to slow
down the regenerative burst characterizing the disease18, but also
to promote a shift to a more oxidative phenotype, that is known
to confer protection from oxidative stress-induced damage13, 15.
We report a robust improvement in dystrophic mice lacking
Nﬁx, which was evident in terms of general muscle structure,
reduced inﬂammatory areas, central nucleation, and ﬁbrotic
deposition. These features were persistent up to 6 months. The
morphological amelioration was also accompanied by reduced
membrane damage and inﬂammation, as demonstrated by EBD,
MIP2 assays, and quantiﬁcation of the number of macrophages in
muscles. Most importantly, mice lacking Nﬁx showed increased
resistance to fatigue and better muscle performance with respect
to controls, in keeping with our observation that these mice are
characterized by a more oxidative phenotype. Conversely, we
show that the dystrophic phenotype is exacerbated when Nﬁx is
overexpressed speciﬁcally in skeletal muscle, and that the
exacerbation correlates with levels of Nﬁx overexpression. Very
interestingly, we observed that both Sgca null and mdx dystrophic
mice lacking Nﬁx are characterized by comparable rescue of the
histopathological signs, regardless of their genetic defect.
These results came from dystrophic animals that genetically
lack Nﬁx since the very early stages of the pathology. Notably, we
demonstrated that silencing of Nﬁx strongly rescues the patho-
logical signs even when the disease has already occurred, pro-
viding the basis for a future translational approach for MD
patients.
To our knowledge, this is the ﬁrst study resulting in such a
signiﬁcant amelioration of the dystrophic pathology as a con-
sequence, at least in part, of a switch toward an oxidative phe-
notype. In fact, previous studies targeting calcineurin expression
were conducted to try to promote slow MyHC positive ﬁbers,
although only in the less severe (with respect to Sgca null mice)
dystrophic mdx mouse model32, 36. These studies proposed
upregulation of utrophin as compensatory mechanism, while in
our hands, utrophin is not upregulated. This supports the concept
that targeting Nﬁx protects from MD acting on different
mechanisms.
Importantly, we are proposing here that delaying regeneration
induces a beneﬁcial effect as a consequence of the delay of the
degeneration–regeneration circuit. This is in evident contrast with
previous studies that, in the past years, tried to recover muscle
function by promoting regeneration10, 11. However, none of these
approaches has been successful when translated to humans12.
Moreover, these studies were based on blockade of myostatin,
which in our hands is not differentially regulated in dystrophic
mice. Notably, our ﬁndings are in line with other recent obser-
vations demonstrating that blockade of myostatin in other dys-
trophic animal models worsens the disease37, 38.
Therefore, we are proposing that Nﬁx exerts its functions
through a double mechanism, involving both a switch to an
oxidative phenotype and a delay of the regenerative process. We
cannot absolutely exclude other mechanisms involved, since Nﬁx
is also expressed by other cell populations such as macrophages
(Saclier et al., unpublished results). Nevertheless, the exacerbated
phenotype observed in the double Sgca null:Mlc1f-Nﬁx2 mice,
where Nﬁx is overexpressed speciﬁcally in muscle cells, clearly
supports the evidence that a slow regenerating and a slow
twitching dystrophic musculature is at the basis of the ameli-
oration/rescue observed. After all, even the soleus (a typical slow
muscle) is itself affected in the dystrophic animals as also human
patients who mainly display a slow musculature, suggesting that
an oxidative phenotype is not sufﬁcient to protect the muscu-
lature from the degeneration.
Our results, beyond the approach used, provide clear and
robust evidence for a wider and ground-breaking concept: forcing
regeneration in a structurally impaired dystrophic muscle actually
leads to an increase of the oxidative stress and an acceleration of
degeneration cycles, which exacerbates the phenotype. The data
presented here demonstrate that the successful strategy is the
opposite. In this sense, any other approach resulting in both
slower regeneration and an oxidative musculature should be
preferred in a dystrophic context.
In particular, the strategy of silencing Nﬁx could be applied in
combination with adeno-associated virus (AAV)-mediated gene
correction39–41. Nﬁx silencing could in fact be used to stabilize
muscle degeneration/regeneration, allowing a longer expression
of the AAV transgene, which on the contrary would be rapidly
lost after treatment as a consequence of the continuous regen-
eration of the infected ﬁbers. This would result in an increased
efﬁciency of the treatment. Alternatively, a “druggable” way to
selectively inhibit Nﬁx expression or its function might be
developed in the future, upon the identiﬁcation of the signaling
regulating Nﬁx and/or the Nﬁx protein structure.
In the long term, the development of drugs targeting Nﬁx
would represent a better, valid strategy. All these aspects give to
our study a strong translational potential.
Methods
Mouse models. Sgca null, Nﬁx null, mdx, and Tg:Mlc1f-Nﬁx2 mice were pre-
viously described17, 26, 35, 42. As described in refs 18, 42, Nﬁx null mice were fed with
a special transgenic mice dough diet (Bioserv). To avoid any possible effect due to
the diet composition, the diet was given to all WT, Sgca null, and mdx mice used as
control mice for single Nﬁx null and double Sgca null:Nﬁx null or mdx:Nﬁx null
mice. Both male and female mice were used. Mice were kept in pathogen-free
conditions and all procedures were conformed to Italian law (D. Lgs no. 2014/26,
implementation of the 2010/63/UE) and approved by the University of Milan
Animal Welfare Body and by the Italian Ministry of Health.
In vivo electroporation. In vivo electroporation was performed on 5-week-old
Sgca null mice, as also described in Rossi et al.18 Animals were anesthetized and 40
μg of control (scramble) or shNﬁx plasmids resuspended in 0.9% salt solution17
were injected in a total volume of 40 μl in tibialis anterior muscles. Muscles were
then immediately electroporated using a pulse generator (ECM 830, BTX) equip-
ped with 5 μm needle electrodes to generate 100 V pulses, with a ﬁxed duration of
20 ms and an interval of 200 ms between the pulses.
Hematoxylin and eosin and Milligan’s trichrome. Hematoxylin and eosin
staining was performed on 7-μm-thick cryosections ﬁxed with 4% paraformalde-
hyde for 10 min at 4 °C. The staining was performed according to standard pro-
tocols. For Milligan’s trichrome staining, sections were ﬁxed for 1 h with Bouin’s
ﬁxative (Sigma-Aldrich) and rinsed for 1 h under running water. Sections were
then rapidly dehydrated to 95% EtOH in graded ethanol solutions, successively
passed in 3% potassium dichromate (Sigma-Aldrich) for 5 min, rapidly washed in
distilled water, stained with 0.1% acid fuchsin (Sigma-Aldrich) for 30 s, washed
again in distilled water, passed in 1% phosphomolybdic acid (Sigma-Aldrich) for
3 min, stained with Orange G (2% in 1% phosphomolybdic acid; Sigma-Aldrich)
for 5 min, rinsed in distilled water, passed in 1% acetic acid (VWR) for 2 min,
stained with 1% Fast Green for 5 min (Sigma-Aldrich), passed in 1% acetic acid for
3 min, rapidly dehydrated to 100% EtOH, and passed in xylene before mounting
with Eukitt (Bio-Optica).
SDH staining. SDH staining was performed on 3-week-old mice. For SDH
staining, freshly cut 7-μm-thick cryosections were used. Sections were incubated in
SDH incubating solution (one tablet of nitrobluetetrazolium dissolved in 0.1 M
sodium succinate–0.1 M phosphate buffer, pH 7.4, all from Sigma-Aldrich) for 1 h
at 37 °C, rinsed in distilled water, rapidly passed in 30%, 60%, 30% acetone (VWR),
and rinsed again in distilled water. Sections were then rapidly dehydrated in graded
EtOH solutions, cleared in xylene, and mounted with Eukitt mounting medium.
ELISA assays. Measurement of MIP-2 concentration was performed on gastro-
cnemius muscle protein extracts. Protein extracts were obtained homogenizing
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minced muscle tissues in tissue lysis buffer (150 mM Tris-HCl, pH 7.5; 1 mM
EDTA, 1% Triton, 150 mM NaCl (all from Sigma-Aldrich)) for 30 s, followed by
lysis on ice for 30 min and by centrifugation at 10,000 r.p.m. at 4 °C to pellet cell
debris. Supernatant was quantiﬁed using DC Protein Assay (Bio-Rad) and 500 μg
of proteins were loaded to perform a MIP-2 ELISA assay (R&D Systems), following
manufacturer’s instructions. Myostatin levels in serum were measured using
Quantikine ELISA GDF-8/Myostatin Immunoassay (R&D Systems), following
manufacturer’s instructions. Blood samples were allowed to clot O/N at 4 °C before
centrifuging for 20 min at 2000×g. Serum samples were separated and maintained
at −20 °C before loading on the ELISA plate.
Evan’s blue dye uptake measurement. Evan’s blue dye (Sigma-Aldrich) solution
(5 mgml−1) was injected intraperitoneally in 8-week-old mice 24 h before sacriﬁce
(10 μl per g of mice). Positivity for Evan’s blue dye was revealed through its
autoﬂuorescence, ﬁxing sections with acetone (VWR) for 10 min at −20 °C, per-
meabilizing them in 1% BSA (Sigma-Aldrich)–0.2% Triton X-100 (Sigma-Aldrich)
for 30 min, and incubating them O/N with rabbit anti-laminin antibody (1:300,
Sigma-Aldrich) to reveal myoﬁber outlines. The day after, sections were washed,
incubated with a goat anti-rabbit 488 secondary antibody (1:250, Jackson Lab),
together with Hoechst (1:250, Sigma-Aldrich), washed again, and ﬁnally mounted
with a ﬂuorescence mounting medium (Dako). Measurement of the percentage of
Evan’s blue dye uptake was performed counting the number of Evan’s blue dye
positive ﬁbers on total muscle section reconstructions, using Image J software.
Diaphragm and TA muscles were counted as the most representative.
Treadmill test. For Treadmill test functional assay, 4-week-old mice were exer-
cised three times, once a week, before recording of their performances. Treadmill
test was therefore performed starting from 7-week-old mice, once a week for
6 weeks. The test was conducted on a treadmill (Bioseb) with a 10% incline,
starting from a speed of 6 cm s−1 and increasing it by 2 cm s−1 every 2 min. For
each test, the time to exhaustion of each mouse was measured.
RNA extraction, reverse transcription PCR, and real-time PCR. Real-time PCR
was performed starting from RNA extracts obtained from muscle tissues homo-
genized and extracted in Trizol Reagent (Invitrogen) following manufacturer’s
instructions. RNA (1 μg) was retro-transcribed to complementary DNA (cDNA)
using iScript cDNA Synthesis Kit (Bio-Rad), and 5 μl of diluted (1:5) cDNA was
used for each sample. Gene expression was quantiﬁed by comparative CT method,
using GAPDH as a reference. Primers used are: Nﬁx fwd
CTGGCTTACTTTGTCCACACTC; Nﬁx rev CCAGCTCTGTCACATTCCAGAC;
GAPDH fwd AGGTCGGTGTGAACGGATTTG; GAPDH rev TGTAGACCATG
TAGTTGAGGTCA; utrophin fwd AAGATGGGAGAAAGCTCTTGGA; utrophin
rev TCGGTTGACATTGTTTAAGGCA; myostatin fwd AAGATGACGATTATG
ACGCTACC; myostatin rev CCGCTTGCATTAGAAAGTCAGA; SDHA fwd
AGAGATGTTGTGTCTCGATCCAT; SDHA rev CTGCAGGTAGACGTGAT
CTTTCT; SDHB fwd AGCAAAGTCTCCAAAATCTACCC; SDHB rev TCAATG
GATTTGTATTGTGCGTA; Cox5A fwd TTGCGTAAAGGGATGAATACACT;
Cox5A rev TTTGTCCTTAACAACCTCCAAGA.
Western blot. Western blot was performed on protein extracts from muscles
homogenized in tissue buffer and processed as described for MIP-2 ELISA assay.
Total protein extracts of 30 μg were loaded for each sample. Images were acquired
using Chemidoc ImageLab software (Bio-Rad). The following antibodies and
dilutions were used: rabbit anti-Nﬁx (1:5000, Geneka Biotechnology), mouse anti-
Vinculin (1:2500, Clone VIN-11-5, Sigma-Aldrich), and IgG-HRP secondary
antibodies (1:10,000, Bio-Rad).
Immunoﬂuorescence. Immunoﬂuorescence was performed on 7 μm cryosections.
Slices were ﬁxed for 10 min at 4 °C with 4% PFA (apart from staining for F4/80 and
dMHC that do not require ﬁxation), washed twice in PBS, and permeabilized with
a solution containing 1% BSA and 0.2% Triton X-100 in PBS, for 30 min at room
temperature. After a blocking for 30 min with 10% donkey or goat serum, slices
were incubated O/N with primary antibodies in PBS-1.5% donkey or goat serum.
The day after, two washes in PBS-1% BSA-0.2% Triton X-100 were performed, and
samples were incubated for 45 min at room temperature with secondary antibodies
(donkey anti goat 488, goat anti rabbit 594, goat anti mouse 488, donkey anti rat
488, and donkey anti rabbit 594 (1:250, Jackson Lab)) and Hoechst (Sigma-
Aldrich). Excess of antibody was washed twice in PBS-0.2% Triton X-100 before
mounting with ﬂuorescence mounting medium (Dako). The following primary
antibodies and dilutions were used: goat anti-collagen I (1:200, Southern Biotech),
rat anti-F4/80 (1:400, Clone CI-A3-1, Novusbio), rabbit anti-laminin (1:300,
Sigma-Aldrich), and mouse anti-dMHC, which detects the Myh3 isoform (1:40,
Clone MONX10806, Monosan).
Image acquisition. Images were acquired with an inverted microscope (Leica-
DMI6000B) equipped with Leica DFC365FX and DFC400 cameras and ×10 and
×20 magniﬁcation objectives. The Leica Application Suite software was used for
acquisition, while Photoshop was used to generate merged images.
Measurement of central nucleation, CSA, and collagen I. Measurement of
central nucleation and myoﬁber CSA was performed on tibialis anterior muscle
sections of mice at 8 weeks (at 10 weeks for mdx and mdx:Nﬁx null mice), using
Image J software. Collagen I quantiﬁcation was performed using a Macro in ImageJ
to identify and quantify collagen I positive areas.
Statistics. All data shown in graph are expressed as mean± SD, apart from graphs
showing CSA distributions, which are expressed as mean±whiskers from min to
max. Statistical analysis between two columns was performed using two-tailed
unpaired Student’s t test, whereas data containing more than two experimental
groups were analyzed with one-way analysis of variance followed by Bonferroni’s
test. *P< 0.05; **P< 0.01; ***P< 0.001; conﬁdence intervals 95%; alpha level 0.05.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the paper and its Supplementary Information ﬁles.
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